Hetty C. de Boer

4.9k total citations · 1 hit paper
73 papers, 3.7k citations indexed

About

Hetty C. de Boer is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Hetty C. de Boer has authored 73 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 22 papers in Hematology and 16 papers in Cancer Research. Recurrent topics in Hetty C. de Boer's work include Angiogenesis and VEGF in Cancer (16 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Platelet Disorders and Treatments (11 papers). Hetty C. de Boer is often cited by papers focused on Angiogenesis and VEGF in Cancer (16 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Platelet Disorders and Treatments (11 papers). Hetty C. de Boer collaborates with scholars based in Netherlands, Germany and United States. Hetty C. de Boer's co-authors include Anton Jan van Zonneveld, Ton J. Rabelink, Eelco J.P. de Koning, C. Verseyden, Frank J. T. Staal, Cindy J.M. Loomans, Maarten B. Rookmaaker, Marianne C. Verhaar, Branko Braam and Philip G. de Groot and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Hetty C. de Boer

71 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Endothelial Progenitor Cell Dysfunction

2004 708 citations C. Verseyden, Hetty C. de Boer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hetty C. de Boer Netherlands	33	1.7k	749	663	620	518	73	3.7k
Bénédicte Hugel France	24	2.3k 1.4×	606 0.8×	1.2k 1.9×	1.1k 1.7×	882 1.7×	25	4.2k
Yohei Maeshima Japan	36	3.0k 1.8×	1.4k 1.9×	534 0.8×	389 0.6×	477 0.9×	94	5.6k
Aurélie S. Leroyer France	29	2.1k 1.2×	654 0.9×	823 1.2×	339 0.5×	741 1.4×	67	3.2k
G Tobelem France	35	1.4k 0.8×	478 0.6×	348 0.5×	982 1.6×	447 0.9×	99	3.5k
Anna Solovey United States	23	1.9k 1.1×	424 0.6×	366 0.6×	927 1.5×	307 0.6×	40	3.6k
Kinta Hatakeyama Japan	35	903 0.5×	458 0.6×	839 1.3×	617 1.0×	869 1.7×	175	3.6k
Alberto Smith United Kingdom	40	1.1k 0.7×	522 0.7×	671 1.0×	593 1.0×	597 1.2×	96	4.2k
Zhiyong Lin United States	26	2.4k 1.4×	584 0.8×	529 0.8×	301 0.5×	393 0.8×	51	3.4k
Jeannette Soria France	27	996 0.6×	639 0.9×	311 0.5×	559 0.9×	234 0.5×	76	2.6k
Stephan Lindemann Germany	28	1.0k 0.6×	429 0.6×	823 1.2×	1.3k 2.1×	984 1.9×	54	3.5k

Countries citing papers authored by Hetty C. de Boer

Since Specialization

Citations

This map shows the geographic impact of Hetty C. de Boer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hetty C. de Boer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hetty C. de Boer more than expected).

Fields of papers citing papers by Hetty C. de Boer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hetty C. de Boer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hetty C. de Boer. The network helps show where Hetty C. de Boer may publish in the future.

Co-authorship network of co-authors of Hetty C. de Boer

This figure shows the co-authorship network connecting the top 25 collaborators of Hetty C. de Boer. A scholar is included among the top collaborators of Hetty C. de Boer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hetty C. de Boer. Hetty C. de Boer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bredewold, Obbo W, Annemarie M. van Oeveren‐Rietdijk, Joris I. Rotmans, et al.. (2024). Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts. Transplant Immunology. 82. 101976–101976. 1 indexed citations

Dólleman, Sophie, Stijn M. Agten, Henri M.H. Spronk, et al.. (2022). Thrombin in complex with dabigatran can still interact with PAR‐1 via exosite‐I and instigate loss of vascular integrity. Journal of Thrombosis and Haemostasis. 20(4). 996–1007. 8 indexed citations

Coenen, Daniëlle M., Sophie Dólleman, Annemarie M. van Oeveren‐Rietdijk, et al.. (2020). SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis. Journal of Thrombosis and Haemostasis. 18(7). 1714–1727. 16 indexed citations

Wang, Gangqi, Margreet R. de Vries, Wendy Sol, et al.. (2020). Loss of Endothelial Glycocalyx Hyaluronan Impairs Endothelial Stability and Adaptive Vascular Remodeling after Arterial Ischemia. Cells. 9(4). 824–824. 13 indexed citations

Sánchez‐Duffhues, Gonzalo, Eleanor Williams, Valeria V. Orlova, et al.. (2019). Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva‐Derived Endothelial Cells. JBMR Plus. 3(11). e10230–e10230. 23 indexed citations

Boels, Margien G. S., Angela Koudijs, M. Cristina Avramut, et al.. (2017). Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy. American Journal Of Pathology. 187(11). 2430–2440. 75 indexed citations

Khedoe, Padmini P. S. J., Stan de Kleijn, Annemarie M. van Oeveren‐Rietdijk, et al.. (2017). Acute and chronic effects of treatment with mesenchymal stromal cells on LPS-induced pulmonary inflammation, emphysema and atherosclerosis development. PLoS ONE. 12(9). e0183741–e0183741. 15 indexed citations

Spronk, Henri M.H., Anne Margreet de Jong, Sander Verheule, et al.. (2016). Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. European Heart Journal. 38(1). 38–50. 116 indexed citations

Rothuizen, T.C., Jacques M.G.J. Duijs, Hetty C. de Boer, et al.. (2016). Promoting Tropoelastin Expression in Arterial and Venous Vascular Smooth Muscle Cells and Fibroblasts for Vascular Tissue Engineering. Tissue Engineering Part C Methods. 22(10). 923–931. 10 indexed citations

10.

Pont, Margot J., M. Willy Honders, Anita N. Kremer, et al.. (2016). Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. PLoS ONE. 11(5). e0155165–e0155165. 13 indexed citations

11.

Bijkerk, Roel, Coen van Solingen, Hetty C. de Boer, et al.. (2015). Silencing of MiRNA-126 in Kidney Ischemia Reperfusion is Associated with Elevated SDF-1 Levels and Mobilization of Sca-1+/Lin- Progenitor Cells. MicroRNA. 3(3). 144–149. 12 indexed citations

12.

Boer, Hetty C. de, Annemarie M. van Oeveren‐Rietdijk, Joris I. Rotmans, et al.. (2013). Activated platelets correlate with mobilization of naïve CD34+ cells and generation of CD34+/KDR+ cells in the circulation. A meta‐regression analysis. Journal of Thrombosis and Haemostasis. 11(8). 1583–1592. 10 indexed citations

13.

Egorova, Anastasia D., Marco C. DeRuiter, Hetty C. de Boer, et al.. (2011). Endothelial colony-forming cells show a mature transcriptional response to shear stress. In Vitro Cellular & Developmental Biology - Animal. 48(1). 21–29. 44 indexed citations

14.

Rabelink, Ton J., Hetty C. de Boer, & Anton Jan van Zonneveld. (2010). Endothelial activation and circulating markers of endothelial activation in kidney disease. Nature Reviews Nephrology. 6(7). 404–414. 110 indexed citations

15.

Xu, Wei, Stefan P. Berger, Leendert A. Trouw, et al.. (2008). Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation. The Journal of Immunology. 180(11). 7613–7621. 113 indexed citations

16.

Boer, Hetty C. de, C. Verseyden, Laurien H. Ulfman, et al.. (2006). Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype. Arteriosclerosis Thrombosis and Vascular Biology. 26(7). 1653–1659. 115 indexed citations

17.

Bloemendal, Haiko J., Hetty C. de Boer, Roel Goldschmeding, et al.. (2004). Activated vitronectin as a target for anticancer therapy with human antibodies. Cancer Immunology Immunotherapy. 53(9). 799–808. 18 indexed citations

18.

Boer, Hetty C. de, Klaus T. Preissner, Bonno N. Bouma, & Philip G. de Groot. (1992). Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin.. Journal of Biological Chemistry. 267(4). 2264–2268. 61 indexed citations

19.

d’Alessio, Patrizia, Giancarlo Castaman, Francesco Rodeghiero, et al.. (1992). In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease ‘Vicenza’ is caused by normal platelet-vWF levels rather than by high vWF-multimers in plasma. Thrombosis Research. 65(2). 221–228. 4 indexed citations

20.

Groot, Philip G. de, C L Verweij, Peter P. Nawroth, et al.. (1987). Interleukin-1 inhibits the synthesis of von Willebrand factor in endothelial cells, which results in a decreased reactivity of their matrix toward platelets.. Arteriosclerosis An Official Journal of the American Heart Association Inc. 7(6). 605–611. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact